Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen
by Zacks Equity Research
Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.
Opioid Overdose Crisis in US Likely to Affect These 3 Stocks
by Sreyoshi Mukherjee
Increasing lawsuits against pharmaceutical companies are likely to impact retailers and distributors.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.96 in the latest trading session, marking a -1.14% move from the prior day.
Mallinckrodt's StrataGraft Tissue Phase III Data Positive
by Zacks Equity Research
Mallinckrodt's (MNK) experimental StrataGraft regenerative tissue meets goals in a late-stage study for the treatment of burns.
J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use
by Zacks Equity Research
J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $8.04, moving +1.26% from the previous trading session.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Apple, American Express, Kraft Heinz and Teva Pharmaceutical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Apple, American Express, Kraft Heinz and Teva Pharmaceutical
Buffett's Best & Worst Performing Stocks Thus Far in 2019
by Tirthankar Chakraborty
So far this year, here are the winners and losers of Oracle of Omaha's favored companies.
Mallinckrodt to Divest Contract Manufacturing Unit, Stock Up
by Zacks Equity Research
Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.
Mallinckrodt (MNK) to Resolve Opioid Cases with Ohio Counties
by Zacks Equity Research
Mallinckrodt (MNK) reaches a settlement in principle with a couple of Ohio counties for opioid litigation.
Novartis Announces Positive Long-Term Data on Migraine Drug
by Zacks Equity Research
Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.
Mallinckrodt Mulls Bankruptcy Ahead of Major Opioid Litigation
by Zacks Equity Research
Mallinckrodt (MNK) plunges as the risk of filing for bankruptcy rises ahead of the multi-district opioid litigation scheduled next month.
Allergan Settles Ahead of Multi-District Opioid Litigation
by Zacks Equity Research
Allergan (AGN) settles with two counties of Ohio for $5 million related to the upcoming multidistrict litigation for opioid-based drug abuse.
Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies
by Zacks Equity Research
Novartis (NVS) MS drug meets primary and secondary endpoints in late-stage studies.
Will Opioid Litigation Take its Toll on Pharma Companies?
by Indrajit Bandyopadhyay
Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.
J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?
by Christopher Vargas
An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.
AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease
by Zacks Equity Research
AstraZeneca's (AZN) Fasenra gets Orphan Drug status for eosinophilic oesophagitis (EoE). A phase III COPD study on Breztri Aerosphere meets primary endpoint.
J&J Up Despite $572M Fine in Oklahoma Opioid Abuse Case
by Zacks Equity Research
A court ordered J&J (JNJ) to pay $527 million in the Oklahoma litigation related to abuse of its opioid-based drugs. The company is facing similar litigation in multiple states.
Case-Shiller Index Nudges Up
by Zacks Equity Research
Case-Shiller Index Nudges Up
J&J to Pay $572M in Opioid Case; Plus Case-Shiller Home Price Read
by Mark Vickery
Johnson & Johnson (JNJ) now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use.
J&J's (JNJ) Opioid Lawsuit Verdict in Oklahoma Due Next Week
by Zacks Equity Research
J&J (JNJ) is facing several litigation in multiple states related to abuse of its opioid-based drugs. A ruling is expected on Aug 26 in a trial filed by the state of Oklahoma.
Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit
by Kinjel Shah
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.
Mallinckrodt (MNK) Stock Down 70.8% YTD on Numerous Lawsuits
by Zacks Equity Research
Mallinckrodt (MNK) crashes 70.8% in the year so far due to various lawsuits and litigations.
Endo Up on Settlement of a Few Cases Related to Opioid Drugs
by Zacks Equity Research
Endo (ENDP) finally has some good news for investors with the settlement of a few cases in Ohio related to opioid medications.